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Abstract
Introduction: Tendon injury is a common problem in athletes, with poor tissue regeneration and a high rate of re-
injury. Stem cell therapy is an attractive treatment modality as it may induce tissue regeneration rather than tissue
repair. Currently, there are no reports on the use of pluripotent cells in a large animal tendon model in vivo.W e
report the use of intra-lesional injection of male, fetal derived embryonic-like stem cells (fdESC) that express Oct-4,
Nanog, SSEA4, Tra 1-60, Tra 1-81 and telomerase.
Methods: Tendon injury was induced using a collagenase gel-physical defect model in the mid-metacarpal region
of the superficial digital flexor tendon (SDFT) of eight female adult Thoroughbred or Thoroughbred cross horses.
Tendon lesions were treated one week later with intra-lesional injection of male derived fdESCs in media or media
alone. Therapy was blinded and randomized. Serial ultrasound examinations were performed and final analysis at
eight weeks included magnetic resonance imaging (MRI), biochemical assays (total DNA, glycosaminoglycan,
collagen), gene expression (TNC, TNMD, SCX, COL1A1, COL3A1, COMP, DCN, MMP1, MMP3, MMP13, 18S) and
histology. Differences between groups were assessed with Wilcoxon’s rank sum test.
Results: Cell survival was demonstrated via the presence of the SRY gene in fdESC treated, but not control treated, female
S D F Ta tt h ee n do ft h et r i a l .T h e r ew e r en od i f f e r e n c e si nt e n d on matrix specific gene expression or total proteoglycan,
collagen or DNA of tendon lesions between groups. Tissue architecture, tendon size, tendon lesion size, and tendon linear
fiber pattern were significantly improved on histologic sections and ultrasound in the fdESC treated tendons.
Conclusions: Such profound structural effects lend further support to the notion that pluripotent stem cells can
effect musculoskeletal regeneration, rather than repair, even without in vitro lineage specific differentiation. Further
investigation into the safety of pluripotent cellular therapy as well as the mechanisms by which repair was
improved seem warranted.
Introduction
Overstrain injuries to weight bearing tendons are com-
mon in human [1,2] and equine [3,4] athletes with many
similarities between the two [5,6]. Commonly injured
tendons include the Achilles tendon in humans and the
superficial digital flexor tendon (SDFT) in the horse.
These injuries are predominantly degenerative in nature,
slow to heal, and rarely regain their original strength and
elasticity [5,7]. This inferior healing leads to prolonged
rehabilitation times and a high re-injury rate [1,7].
Despite improvements in early detection, advances in
rehabilitation techniques, and numerous new biologic
and cellular therapies, a consistently successful treatment
regimen has yet to be developed [5,7-9].
Due to the low cellularlity and low mitotic activity of
tendons, intrinsic tendon repair is largely performed by
cells of the endotenon and epitenon with some prolifera-
tion of tenocytes at the perimeter of the lesion [10].
Extrinsic repair may be influenced by microvascular peri-
cytes and endothelial cells associated with blood vessels
[11]. The paucity of an appropriate cell for tendon regen-
eration may explain the prolonged healing times, disorga-
nized scar tissue formation, and inferior mechanical
properties of healed tendons [12]. This fact has led to an
interest in cellular therapies for tendon injury that may
recapitulate tendon development, resulting in tendon
regeneration [13]. Adult derived mesenchymal stromal
(stem) cells (MSCs), the multipotent precursor cells of
* Correspondence: ajn1@cornell.edu
1Department of Clinical Sciences, Comparative Orthopaedics Laboratory at
Cornell University, Ithaca, NY, 14850 USA
Full list of author information is available at the end of the article
Watts et al. Stem Cell Research & Therapy 2011, 2:4
http://stemcellres.com/content/2/1/4
© 2011 Watts et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.connective tissues, have been used toward this goal
experimentally in rats [14,15], rabbits [16], horses [17-19]
and sheep [20], and empirically for clinical tendon injury
in horses [21,22] for the past several years. Despite signif-
icant improvements to re-injury rates [21], and minor
improvements to histologic architecture [17,18], MSCs
have not induced the degree of tendon regeneration that
is seen in injured fetal tendon [23]. Utilizing a cell line
with greater plasticity and proliferative capacity than
adult multipotent MSCs, may better contribute to tendon
regeneration [24]. To date, there have been no studies
exploring the use of pluripotent cells in the treatment of
tendon injury in a large animal model.
Currently, there is no successful method for isolation
of equine ESCs [25]. In order to avoid necessary genetic
manipulations of induced pluripotent stem (iPS) cells
[26-29], an allogenic cell line (OK-100™; Celavet, Inc.,
Oxnard, CA, USA) derived from equine fetal tissue and
induced to express markers of pluripotency through cul-
ture conditions was utilized. The objective of this study
was to examine the effect of a pluripotent cell versus
placebo control on tendon healing in a large animal
model of experimental tendon injury.
Materials and methods
Animals
Eight adult female Thoroughbred (n =7 )o rT h o r -
oughbred cross (n = 1) horses, ranging in age from
three to seven years, without clinical or ultrasonographic
evidence of tendon injury were used. All horses had
undergone rigorous athletic training prior to inclusion
in the study. Horses were housed separately, in box
stalls, and allowed to acclimate to the environment for
≥2 weeks prior to study initiation. All invasive proce-
dures were performed by experienced board certified
veterinary surgeons. This study was approved by and
performed according to guidelines of the university’s
Institutional Animal Care and Use Committee.
Cell isolation, culture
To allow for testing of a pluripotent cell, a commercially
available cell line (OK-100™) was used. Briefly, the cell
line was prepared from an equine fetus obtained early in
gestation by uterine flushing. Fetal tissue, specifically
brain, spinal cord, liver and heart, was dissected and
each organ was separately minced with microscissors
and then triturated with Pasteur pipettes until a single
cell suspension was obtained. Cells were cultured in
non-adherent culture flasks in serum free culture med-
ium of Eagle’s essential medium (Lonza RR116254,
Walkersville, MD, USA) supplemented with B27 (Invi-
trogen 17504, Carlsbad, CA, USA), calcium chloride
(Fisher Scientific, Pittsburgh, PA, USA), Epidermal
Growth Factor (Peprotech 100-15, Rocky Hill, NJ, USA),
Basic Fibroblast Growth Factor (Peprotech 100-18B,
Rocky Hill, NJ, USA), Transforming Growth Factor
A l p h a( P e p r o t e c h1 0 0 - 1 6 A ,R o c k yH i l l ,N J ,U S A ) ,L e u -
kemia Inhibitory Factor (Millipore LIF1010, Temecula,
CA, USA), L-Glutamine (Invitrogen 25030, Carlsbad,
CA, USA), and a nitrogen supplement (Invitrogen
17502, Carlsbad, CA, USA) all added at proprietary con-
centrations (patent 7632681Celavie Biosciences, LLC,
Reading, PA, USA). Cells were passaged approximately
weekly by centrifugation for five to six months. Four
days after each passage, 4 mL of fresh culture medium
was added to culture flasks. Beginning at three months,
an aliquot of cells was tested for markers of pluripo-
tency and this was repeated monthly until cells were
>70% positive for Oct-4, nanog, telomerase, SSEA4, Tra
1-60 and Tra 1-81 and 100% negative for major histo-
compatibility complex proteins I and II and p53 (data
not shown). Once this was confirmed, chromosomal
microarray was used to confirm that genomic deletions
or duplications had not occurred during the culture per-
iod (data not shown).
Study design
The study consisted of two randomly assigned groups:
group A (stem cell treated tendons; n =4 ;f d E S C )a n d
group B (placebo treated tendons; n =4 ;C O N T ) .O n e
week after tendon injury, treatment injections were per-
formed. Ultrasound examinations were performed every
two weeks, thereafter. Eight weeks after treatment injec-
tion, animals were euthanized, magnetic resonance ima-
ging was performed and tissues were collected (Figure 1).
Other than an off-site control officer, all investigators
were blinded to treatment group identification until the
study was completed and all assays were performed.
Treatment group (A or B) was revealed for statistical ana-
lysis. Once all analyses were completed, treatment group
identification (fdESC or CONT) was disclosed.
Tendon injury induction
Collagenase-induced lesions were created in the tensile
region of the superficial digital flexor tendon (SDFT) of
one randomly selected forelimb using filter sterilized bac-
terial collagenase type I (Sigma, St. Louis, MO, USA).
Forelimb selection (left or right) was made by a coin toss
for the first horse and then alternated for each subsequent
horse. Thirteen hundred units of collagenase was delivered
as a gel to a columnar physical defect centered within the
tensile region of the SDFT tendon (16 to 18 cm distal to
the accessory carpal bone; DACB) using a 16 gauge 8.89
cm Weiss Epidural needle with a Tuohy tip (BD, Franklin
Lakes, NJ, USA) inserted under ultrasonographic guidance,
as modified (Watts AE, Yeager AE and Nixon AJ, Sub-
mitted) from previous descriptions [17,30,31]. The study
forelimb was bandaged.
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One week post collagenase tendon injury induction (t = 0
weeks), tendon lesions were treated with two ultrasonogra-
phically guided intra-lesional treatment injections. The day
before treatment injection, three million fdESCs, resus-
pended in 1.5 mL culture media, or 1.5 ml culture media
alone for placebo injection, were packaged in 2 mL coded
cryovials and transported overnight to the animal facility.
For injection, local anesthesia at the sites of needle inser-
tion was achieved with 1 to 3 ml lidocaine (20 mg/ml) in
the subcutaneous tissue and standing sedation (xylazine 0.5
mg/kg IV and butorphanol 0.01 mg/kg IV). Treatment
injection to the lesion was performed with 25 gauge needle
entry at 16 and 18 cm DACB, directed from palmarolateral
to dorsomedial. At the time of treatment injection, horses
were given anti-inflammatory medications (phenylbutazone
4.4 mg/kg bwt IV and dexamethasone 0.04 mg/kg bwt IV).
Non-steroidal anti-inflammatory medication was continued
for two days (phenylbutazone 2.2 mg/kg PO q24 h). Horses
were confined individually to box stalls for the duration of
the study and their treated forelimb was bandaged for the
first five weeks after lesion induction.
Lameness/reaction data
Physical examination was performed and vital para-
meters were recorded every 12 hours, and bandage
changes (up to five weeks after lesion induction) and
limb examinations were performed daily throughout the
study. Lameness at a walk was assessed every six hours
for three days following lesion induction (t = -1 weeks)
a n dt r e a t m e n ti n j e c t i o n( t=0w e e k s )a n de v e r y
12 hours throughout the remainder of the study.
Ultrasound
Ultrasound examinations were performed prior to
admission to the study (baseline) and at t = 0, 2, 4, 6,
and 8 weeks after treatment injection. Ultrasound ima-
ging was performed by a board-certified veterinary radi-
ologist (AEY) using a real-time ultrasound machine
(iU22, Philips Healthcare, Amsterdam, The Netherlands)
equipped with broad-band technology and linear probes
of high frequency (5 to 12 MHz). A template was used
to ensure accurate repetition of tissue gain settings,
focus, and depth of tissue penetration. Longitudinal and
transverse ultrasound images were acquired and tendon
cross-sectional area (TCSA), lesion cross-sectional area
(LCSA), and a longitudinal linear fiber pattern score
were measured by the same ultrasonographer at 16 cm
DACB. The LCSA as a percentage of TCSA was calcu-
lated for relative lesion cross-sectional area (RLCSA).
Tissue harvest and magnetic resonance imaging
Horses were euthanized by pentobarbital overdose at
eight weeks post treatment injection and their treated
forelimb was collected for immediate magnetic reso-
nance imaging (MRI) with a 0.3 Tesla magnet (Vet MR,
Esaote, Genova, Italy). Limbs were positioned in exten-
sion for T1 and T2 image acquisition in the sagittal and
transverse planes. Measurements of TCSA and LCSA
based upon the area of hyperintense signal were made
at 16 cm DACB on T1 images. The lesion was also
graded for the intensity of increased MR signal on T1
images (0 = normal; 1 = mild increase; 2 = moderate
increase; 3 = marked increase; 4 = intense increase,
equal to bone marrow signal).
Following MRI, limbs were dissected under RNase free
conditions and samples were collected from the center
of the tendon lesion at 16 cm DACB extending into the
surrounding normal tendon. Samples were snap-frozen
in liquid nitrogen, pulverized in a freezer-mill and
stored at -80°C until use, or fixed in 4% paraformalde-
hyde at 4°C for 72 hours.
RNA and DNA isolation and qPCR
Total cellular RNA was isolated from pulverized tissue
using a commercially available RNA extraction kit (Per-
fectPure RNA Fibrous Tissue Kit, 5 Prime, Gaithersburg,
MD, USA). Genomic DNA was isolated from pulverized
t i s s u eu s i n gac o m m e r c i a l l ya v a i l a b l eg e n o m i cD N A
extraction kit (PureLink Genomic DNA kit, Invitrogen,
Figure 1 Study timeline. CONT, placebo control; fdESC, fetal derived embryonic-like stem cells; MRI, magnetic resonance imaging; U/S,
ultrasound.
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designed using equine specific sequences published in
Genbank (Additional File 1 Table S1). Genomic DNA
was removed from RNA samples prior to PCR, by DNase
I digestion. RNA and genomic DNA quality was assessed
by spectrophotometry at 260:280 nm and by 1% agarose
gel electrophoresis (data not shown). Total RNA was
reverse transcribed and amplified using the One-Step
RTPCR technique and the ABI PRISM 7900HT Sequence
Detection System (Applied Biosystems, Life Technolo-
gies, Carlsbad, CA, USA). All samples for each molecule
were assessed at the same time on the same qPCR plate
to minimize variation. The qPCR program included
reverse transcription at 48°C for 30 minutes and denatur-
ing at 95°C for 10 minutes, followed by 40 cycles of 90°C
for 15 seconds and 60°C for 1 minute. For gene expres-
sion, each well of the qPCR plate was loaded with 10 ng
of RNA in 20 μl. For DNA, several different loading con-
centrations were utilized, including 10, 25, 50, 100 and
2 0 0n go fD N Ap e rw e l la n dt h en u m b e ro fm e l t i n ga n d
annealing cycles was increased from 40 to 55. Other than
18S, a standard curve was generated from equine specific
plasmid DNA for each gene at known concentrations to
allow copy number estimation. The primers and dual-
labeled fluorescent probe (6-FAM as the 5’ label (reporter
dye) and TAMRA as the 3’ label (quenching dye)) were
designed using Primer Express Software version 2.0b8a
(Applied Biosystems) using equine specific sequences
published in Genbank. All samples were run in triplicate
on the qPCR plate and total copy number per ng of RNA
of each gene was obtained from a standard curve and
normalized to 18 S gene expression for collagen types I
and III (COL1A1, COL3A1), decorin (DCN), cartilage oli-
gomeric matrix protein (COMP), tenascin-C (TNC),
tenomodulin (TNMD), scleraxis (SCX) and matrix metal-
loproteinases-1, 3 and 13 (MMP1, MMP3, MMP13).
Biochemical analysis
Pulverized tendon samples were lyophilized for biochem-
ical assays. For total glycosaminoglycan and total DNA
assay, samples were digested in papain (1 mL papain
(0.5 mg/ml)/10 mg lyophilized tendon) at 65°C for 4 and
24 hours, respectively. The samples were mixed with
dimethylmethylene blue dye for glycosaminoglycan quan-
tification by colorimetric assay [32] and bisbenzimide
compound for DNA quantification by fluorometric assay
[33] in triplicate aliquots. Total soluble collagen content
was determined in triplicate aliquots using the Sircol
Assay (Biocolor LTD., Carrickfergus, Northern Ireland,
UK) according to the manufacturer’s directions for pepsin
soluble collagens with modifications as previously
described [34].
Histology
Fixed longitudinal tissue sections were softened in 4%
phenol in 70% alcohol for five days [31,35] embedded in
paraffin, sectioned and stained with hematoxylin and
eosin (H&E) or Picrosirius Red and examined under
white light and polarized light microscopy. Sections
were also prepared for fluorescent in situ hybridization
with probes produced using nick translation against
genomic SRY, [GenBank: EU599187.1] [36]. All slides
were examined by two blinded investigators (AJN and
AEW), using a calibrated reticule to sequentially exam-
ine across and down the entire tendon section, under
low power and high power where appropriate for cell
detail, to derive a complete histologic impression. For
fluorescent in situ hybridization, slides were character-
ized as being positive or negative for probe hybridiza-
tion. For routine histology, scores were assigned for two
sections from each tendon (proximal and distal within
the lesion, centered at 16 DACB). All tendon parameters
were scored from l (normal) to 4 (severe changes) for:
tenocyte shape, tenocyte density, free hemorrhage, neo-
vascularization, perivascular cuffing, collagen fiber line-
arity, collagen fiber uniformity and polarized light
crimping. Scores from both segments (proximal and dis-
tal) and both observers were averaged. This grading
scheme expands on previously described systems which
utilize an eight-parameter, four-point score [37-39].
Statistical analyses
Numerical data were tested for normality. Once a non-
normal distribution was confirmed, non-parametric sta-
tistics were utilized. Differences between treatment
groups were tested using Wilcoxon’s rank sum analysis.
For ultrasound and MRI data where we expected fdESC
treated tendons to be smaller, with higher fiber pattern
scores and less tissue signal, a one-sided test was uti-
lized. For all other data, a two-sided test was utilized.
Repeated measures analysis was performed within each
g r o u po nu l t r a s o u n dd a t aa td iffering time points using
Wilcoxon’s signed rank tests. Except for repeated mea-
sures analysis, all ultrasound data were normalized as a
percent of the baseline measurement prior to lesion
induction (baseline) or the score of the lesion on the
first day of treatment at t = 0 weeks. Gene expression,
histologic scores, MRI measurements, and biochemical
data were reported as a median and 95% confidence
interval. Ultrasound data from all time points were
reported with box plots, as a median and quartiles. To
test for differences in post-treatment lameness (yes/no),
aF i s h e r ’s exact test was used. For all tests, Statistix
9 software (Analytical Software, Tallahassee, FL, USA)
was used and significance was set at P < 0.05.
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Lameness/reaction data
The day of treatment injection, two fdESC treated
h o r s e sh a dm i l dl a m e n e s sa taw a l kp r i o rt ot r e a t m e n t
injection and no lameness was appreciable in any of the
CONT treated horses. This proportion was not different
(one-tailed P = 0.21). In the days following treatment
injection, the same two fdESC treated horses that were
lame prior to injection, developed increased lameness
and required extension of analgesic/anti-inflammatory
medication (phenylbutazone) duration by six and seven
days beyond routine therapy and two CONT treated
horses developed increased lameness, only one of which
required extension of analgesic/anti-inflammatory medi-
cation (phenylbutazone) duration by five days. No lame-
ness was noted at a walk in either group throughout the
remainder of the study (t = 1 to 8 weeks).
Ultrasound data
Normalized lesion CSA was significantly lower in fdESC
treated tendons compared to CONT tendons at t = 4
weeks (one-tailed P = 0.02) and showed a trend for smal-
ler CSA at t = 8 weeks (one-tailed P =0 . 1 ;F i g u r e2 A ) .
Normalized tendon CSA was significantly lower in fdESC
treated tendons compared to CONT tendons at t = 4
(one-tailed P = 0.02) and eight weeks (one-tailed P =
0.03) and showed a trend for smaller CSA at t = 6 weeks
(one-tailed P = 0.06; Figure 2B). Normalized relative
lesion CSA was significantly lower in fdESC tendons
compared to CONT tendons at t = 4 weeks (one-tailed
P = 0.02). Normalized fiber pattern score, was signifi-
cantly higher (better) for fdESC treated tendons at t = 8
weeks (one-tailed P = 0.02; Figure 2C).
On paired analysis, within the fdESC treated tendons
(one-tailed P = 0.05) but not the CONT treated tendons
(one-tailed P = 0.1), there was a trend for higher (better)
fiber pattern score at t = 8 weeks versus t = 0 weeks.
From two weeks after treatment injections (t = 2
weeks) needle tracts were visible ultrasonographically at
16 and 18 cm distal to the accessory carpal bone in all
CONT treated tendons at all time-points. During the
same period (t = 2 to 8 weeks), needle tracts were visi-
ble, but difficult to discern in two fdESC treated ten-
dons. At the completion of the study, needle tracts
remained visible in all CONT tendons and only two
fdESC tendons (Figure 3). This proportion was not sta-
tistically different (one-tailed P = 0.2).
Magnetic resonance imaging
Tendon lesions were identified by increased signal inten-
sity in all tendons (Figure 4). Tendon CSA made on MR
images were not different between groups (Table 1).
There was a strong trend of reduced relative CSA and
reduced lesion CSA of fdESC treated tendons compared
to that of CONT tendons (one-tailed P =0 . 0 5a n dP =
0.06, respectively; Table 1). Lesion signal intensity scores
for fdESC tendons were lower (more normal) but this
was not statistically significant (Table 1).
Figure 2 Ultrasound measurements. Normalized (A) lesion and
(B) tendon cross-sectional area (CSA) and (C) linear fiber pattern
score for fetal-derived Embryonic-like Stem Cells (fdESC) and
placebo control (CONT) treated tendons at time points post
treatment injection in weeks. Asterisks mark significantly lower (A, B)
or significantly higher (C) values for fdESC than CONT treated
tendons (one-tailed P < 0.05).
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fetal-derived Embryonic-like Stem Cells or B) placebo control injections. Lateral is to the right. Dotted lines outline the superficial digital flexor
tendon and lesion. Arrowheads identify remaining treatment injection needle tracts.
Figure 4 Transverse T1 MR images.I m a g e sw e r em a d ea t1 6c md i s t a lt ot h ea c c e s s o r yc a r p a lb o n e ,p o s tm o r t e m ,e i g h tw e e k sa f t e r
treatment injection with A) fetal derived Embryonic-like Stem Cells and B) placebo control. Lateral is to the right. Arrow-heads outline the
treated tendon in the first image of each group.
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No peritendinous adhesions were noted during dissection
in either group. Once dissected free, tendons from both
groups were visibly enlarged, centered at 16 cm DACB,
and had minimal peri-tendinous reaction (Additional
File 2, Figure S1). Focal pink discoloration was present
superficially in all tendons proximally, at the site of needle
insertion for tendon injury induction and distolaterally, at
the sites for treatment injection (Additional File 2, Figure
S1). Although no scores were assigned, fdESC treated ten-
dons appeared smaller at 16 cm DACB, had less peri-tendi-
nous reaction and treatment injection sites were less
obvious. On cut section, lesions were hemorrhagic, glis-
tened and bulged from the cut surface in all tendons
(Additional File 2, Figure S1).
Quantitative PCR
Good quality RNA and DNA was obtained from all
samples (data not shown). RNA concentrations from
80 mg of tissue (wet weight) was not different between
groups (2-tailed P-value = 0.2; fdESC median 517 ng/μl,
range 318 to 670 ng/μl; CONT median 370 ng/μl, range
293 to 513 ng/μl). DNA concentration from 25 mg of
tissue (wet weight) was significantly lower in fdESC ver-
sus CONT samples (2-tailed P = 0.04; fdESC median 31
ng/μl ;r a n g e2 7t o3 5n g / μl; CONT median 41 ng/μl;
range 34 to 49 ng/μl). There were no significant differ-
ences in anabolic (COL1A1, COL3A1, DCN, TNC or
COMP), catabolic (MMP1, MMP3 or MMP13)o rp h e -
notypic (SCX, TNMD) gene expression between groups
(Additional File 3, Table S2). There was no amplification
of SRY above the level of no template controls, in either
group, at any of the tested loading concentrations.
Biochemical analyses
There were no significant differences in DNA (two-
tailed P-value = 0.09), glycosaminoglycan, or total col-
lagen content between fdESC tendons and CONT ten-
dons (Additional File 3, Table S2).
Histology
Cumulative histology scores were significantly different
(more normal) for fdESC treated tendons compared to
CONT tendons (Figure 5; Table 2). Several individual
parameters were significantly different (more normal) in
fdESC treated tendons compared to controls (Table 2).
No individual parameters were higher (less normal) in
fdESC treated tendons compared to CONT. In situ
hybridization with probes against equine SRY demon-
strated the occasional persistence of injected fdESC cells
in all fdESC treated tendons but not in the CONT ten-
dons (Figure 6).
Discussion
This blinded, placebo-controlled, large animal, short-
term (eight-week) experiment revealed substantial and
clinically relevant improvement in the healing of tendon
injury after intra-lesional injection of pluripotent stem
cells. Such dramatic architectural improvements have
not been shown previously with any treatment modality,
including the multipotent, autogenous MSC or ADSC
[17,19].
Despite widespread use of thec o l l a g e n a s ee n z y m a t i c
degradation model of tendon injury to test various ther-
apeutics, including fat derived and bone marrow derived
autogenous MSCs, no large animal study to date has
demonstrated measureable differences in any parameter,
other than small improvements in histologic grading
[17,19]. In the study reported here, fdESC treated ten-
dons had significant structural improvement on MRI
and ultrasound, compared to CONT treated tendons;
fdESC treated tendons were smaller and had smaller
lesions with better lesion fill and greater return to more
normal linear fiber pattern. In clinical equine tendon
injury, other than severity of the initial lesion, the devel-
opment of normal fiber pattern is the single most pre-
dictive measure of successful long term outcome [40].
Therefore, the improved linear fiber pattern scores in
fdESC treated tendons demonstrate significant and clini-
cally relevant superior healing in the fdESC group, and
suggest at least faster injury resolution, if not an
improvement in long term outcome. Although there is
little available data on the MRI appearance of healing
tendons, it is known experimentally that reduced lesion
signal intensity is correlated with tendon mechanical
recovery [41] and reduction in pain [42]. Therefore, the
Table 1 Tendon and lesion measurements based on transverse T1-weighted MRI at eight weeks
Fetal-derived Embryonic-like Stem Cell treated tendon Placebo control treated tendon
Median 95% Confidence Interval Median 95% Confidence Interval One-tailed P
Relative CSA 0.25 0.1566 to 0.3573 0.4 0.1654 to 0.7040 0.06
Lesion CSA 0.34 0.1463 to 0.5407 0.53 0.1069 to 1.1942 0.06
Tendon CSA 1.28 0.9489 to 1.6776 2.0 1.0088 to 1.9261 0.3
Signal Intensity 0.5 -0.7 to 2.3 2.0 0.2 to 4.3 0.07
Measurements of the superficial digital flexor tendon and lesion were made 16 cm distal to the accessory carpal bone. Tendon, lesion and relative lesion cross-
sectional area (CSA) and signal intensity were assessed.
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P = 0.07) and trend for reduced lesion and relative CSA
on MRI (one-tailed P =0 . 0 6 )i nf d E S Ct r e a t e dt e n d o n s
corroborates better tendon injury resolution.
In a clinical report of the use of MSCs for flexor ten-
don injury in horses, lesions resolved following treat-
ment; however, needle tracts from treatment injections
remained visible on all follow-up ultrasound examina-
tions [21]. Therefore, the inability to find needle tracts
in two fdESC treated tendons and difficulty discerning
needle tracts in the other two fdESC treated tendons,
although not statistically significant, is remarkable, and
may represent a major change in the lesion environ-
ment, occurring as soon as two weeks after the treat-
ment date. Additionally, during gross examination at
eight weeks, needle insertion sites for the treatment
injection were grossly less obvious in fdESC treated ten-
dons (Additional File 2, Figure S1).
Table 2 Histologic scoring
Tendon parameter Fetal-derived embryonic-like stem cell treated tendon Placebo control treated tendon Two-tailed P
Cell shape 1.0 (0.9 to 1.3) 2.0 (1.8 to 2.3)* <0.0001
Cell density 1.0 (2.0 to 2.0) 2.75 (2.3 to 3.0)* 0.0002
Free hemorrhage 1.0 (0.9 to 1.7) 1.75 (1.1 to 2.4) 0.1
Neo-vascularization 2.0 (1.4 to 2.2) 2.0 (1.2 to 2.3) 0.7
Perivascular cuffing 1.5 (1.1 to 2.0) 1.0 (0.83 to 1.4) 0.1
Collagen linearity 2.0 (1.3 to 2.1) 2.75 (2.4 to 3.0)* <0.0001
Collagen uniformity 2.0 (1.4 to 2.1) 3.0 (2.8 to 3.1)* <0.0001
Polarized crimping 1.5 (1.2 to 2.1) 3.0 (2.7 to 3.3)* <0.0001
Epitenon thickening 2.3 (2.0 to 2.6) 3.0 (2.6 to 3.5)* 0.0009
Cumulative Score 15.4 (12.6 to 17.8) 20.8 (19.0 to 23.0)* <0.0001
Histologic scores for fetal-derived embryonic-like stem cell treated tendon and placebo control treated tendon reported as median (95% confidence interval).
Significant differences between treatment groups are marked by an asterisk (two-tailed P < 0.05) and the two-tailed P-values are listed.
Figure 5 Longitudinal histology. This figure shows 50× and 200× magnification of longitudinal sections of superficial digital flexor tendon
stained with H&E and Picrosirius Red for A) fetal-derived Embryonic-like stem cell treated tendon and B) placebo control treated tendon.
Picrosirius images shown under polarized light. Bars = 200 μm.
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Page 8 of 12Despite its many similarities, the collagenase model of ten-
don injury does not totally mimic the insidious and degener-
ate etiopathogenesis of many forms of naturally occurring
flexor tendon injury in man. However, the clinical relevance
of this model to the final acute disruption after months or
years of chronic tendon injury, is supported by the evalua-
tion of gross, biochemical and histopathological changes,
clinical signs, mechanical characteristics, and MRI and ultra-
sonographic findings following the induction of injury
[43,44]. Additionally, the collagenase gel model allows the
generation of a homogenous tendon lesion in a controlled
group of animals and, therefore, improved ability to detect
differences between treated and control arms of the study.
The equine mid-metacarpal SDFT is a large, weight bearing
tendon that is easily accessible, is not confined to a synovial
sheath, and in the equine athlete is commonly affected by
naturally occurring over-stretch tendon injury compounded
on previous microfiber disruption, similar to tendinopathies
of the human Achilles tendon [5,6]. Another major benefit
of this model in testing cellular therapies for tissue regenera-
tion is the creation of a confined lesion, surrounded by nor-
mal tendon, which is a common feature of Achilles tendon
(human) and SDFT (equine) injury. This allows the direct
and focal application of cellular therapies to a closed envir-
onment, where cellular differentiation can occur through
naturally occurring biochemical cues, biomechanical forces,
growth factors, and adjacent cell signaling. This is in direct
contrast to rodent and small animal models where acute sur-
gical transection of flexor tendons is utilized and tendons are
of insufficient size to allow confined and directed focal ther-
apy [45]. However, a limitation of this model is the inability
to test therapies in a large number of animals, resulting in a
study that may be underpowered. This is due to the signifi-
cant cost of housing, buying and caring for these animals
and the strong emotional and ethical considerations in their
use and sacrifice [46].
An additional limitation to this study was the short
term end-point which was selected to assess the acute
effects of the cells on tendon cell population, organiza-
tion, and behavior. Analysis at eight weeks was selected
as it was the earliest time-point that structurally orga-
nized tissues, and, therefore, potential differences, were
expected to be detectable. Despite the small group sizes
(n = 4), several parameters were significantly different
between groups and a few parameters were different as
early as four weeks after treatment injection, providing
strong evidence for improved healing due to fdESC ther-
apy. However, the lack of significant differences in para-
meters such as total DNA and gene expression should
be viewed with caution, as a higher powered study may
have better identified differences if they existed. A final
limitation of this model was the inability to determine
the mechanism by which fdESC injection improved
healing, that is, trophic factors, cell replacement or
other mechanisms.
Both collagen type I and collagen type III are upregu-
lated in tendons following injury, with increased gene
expression (COL1A1 and COL3A1) and protein content
Figure 6 In situ hybridization longitudinal histology. 400× magnification of in-situ hybridization against genomic SRY in A) fetal-derived
Embryonic-like stem cell treated tendon and B) placebo control treated tendon. Bar = 50 μm.
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Page 9 of 12(type III) [47]. Despite its upregulation in healing tendon,
collagen type III content remains low compared to col-
lagen type I [48] and its exact role in tendon healing is
largely unknown. Certainly lower collagen type I to col-
lagen type III ratios indicate scar tissue repair rather than
tendon regeneration; however, collagen ratios generated
during tendon tissue regeneration rather than repair are
not strictly known. In this study, there were no differ-
ences in total collagen content and ratios of COL1A1:
COL3A1 gene expression between fdESC and CONT
treated tendons, which may reflect the importance of tis-
sue organization during healing rather than tendon tissue
constituents. The improved collagen fiber diameter and
alignment seen histologically, as well as improved linear
fiber pattern seen ultrasonographically, and reduced MR
signal intensity, suggest that although total collagen con-
tent is not different, there are improved collagen charac-
teristics in the fdESC treated tendons.
While compositional parameters such as gene expres-
sion and proteoglycan and collagen content accurately
reflect constituents of the healing tendon, they do little
to measure the organization of the tendon. Structural
assessment data indicated fdESC treated tendons had
better histologic scores and improved MRI and ultra-
sound measurements and scores, compared to CONT
treated tendons. These findings, and the lack of signifi-
cant differences in biochemical parameters (DNA, glyco-
saminoglycan, and total collagen content) and gene
expression data between fdESC and CONT, suggest that
the predominant effect of fdESCs on tendon healing is
through tendon structural organization rather than cell
numbers or anabolic gene expression. Alternatively, loca-
lized changes, especially in gene expression, could have
been missed due to total homogenization of the tissue
samples, leading to incorporation of enough surrounding
normal tendon to mask any significant differences
between treatment groups [49]. However, this seems
unlikely given the size of equine tendons, allowing careful
collection of lesion tissue and immediately adjacent ten-
don tissue. Additionally, tendon healing is a slow process,
normally taking up to 18 months to occur. Therefore,
this study is likely to have fallen short of the ultimate
result, and it is possible that gene expression differences
would be apparent in longer term trials.
Although there was no statistically significant differ-
ence in total DNA content determined by fluorometric
assay, there was a trend toward lower total DNA content
in fdESC treated tendons (two-sided P =0 . 0 9 ) .T h i s
could be interpreted as the failure of injected fdESC cells
to persist within the lesion. Alternatively, we suggest that
injected fdESC cells induced tendon regeneration leading
to fewer cells and the accumulation of more normal, less
cellular, tendon matrix, with fewer but more functional
tenocytes. Significantly reduced concentrations of DNA
isolated during genomic DNA preparations from fdESC
tendons compared to CONT tendons, and a trend
toward reduced total DNA content during quantitative
fluorometric assay, corroborate the histologic findings
indicating fdESC tendons were less cellular.
Although MSCs modulate immune function [50], no
such effects have been reported for pluripotent stem cells,
and the risk of using allogenic pluripotent stem cells is
poorly defined. In this study, no adverse effects due to the
use of allogenic cells were expected because the cell line
did not express major histocompatibility proteins, and
none were noted. The reduced cell density, improved cell
shape, lack of inflammatory infiltrate or change in vascu-
larity on histologic sections, minimal peri-tendinous reac-
tion grossly, lack of differences in post treatment injection
lameness, and reduced MR signal suggest that there was
minimal reaction to allogenic fdESCs, despite lack of
immunosuppressant therapy. Additionally, the risk for ter-
atoma formation in immune competent animals with
transplant of a pluripotent cell line is unknown. A tera-
toma assay was not performed for the cell line OK100™.
However, teratoma formation was not seen in other fetal-
derived cell lines used for human neurodegenerative dis-
ease trials [51]. Additionally, the possibility of teratoma
formation seems unlikely given that the cells are not true
embryonic stem cells as they are negative for alkaline
phosphatase staining of colonies and are derived from
fetal tissue, rather than embryos (data not shown; Celavet,
Inc.). Although there was no evidence of teratoma forma-
tion, it is important to note that transplant cell numbers
were relatively low and this was a short term experiment
using a small number of animals. Given the small number
of horses used in this study, safety should be confirmed in
a larger number of animals, longer term.
The use of male derived fdESCs in female recipient
horses was utilized to identify cell transplantation persis-
tence without genetic or cellular modification. Cellular
persistence was documented with in situ hybridization on
histologic sections, although it was an unusual event, and
was not corroborated by PCR amplification of the SRY
gene. Low cell survival may be due to the immunogenicity
of male cells in female animals with chronic rejection
occurring secondary to antibody responses to Y-chromo-
some encoded minor histocompatibility antigens prevent-
ing long-term engraftment [52,53]. It is possible that
injecting genetically or membrane dye labeled same-sex
cells would better gauge and allow for cell survival in fol-
low-up studies [54]. Finally, this study does not define
whether the fdESCs had an effect through exogenous cell
replacement, local cytokine modulation, immune modula-
tion, or the stimulation of trophic factor synthesis. Cer-
tainly, the rarity of long term cell survival would suggest
that it is less likely exogenous cell replacement, and may
be one, or all of the latter factors.
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In conclusion, these findings support the efficacy of
p l u r i p o t e n ts t e mc e l l sf o r the treatment of tendon
injury. Despite low long term survival of injected cells,
intralesional injection with fdESCs resulted in signifi-
cantly better ultrasonographic measurements and scores,
significantly better histological scores and a strong trend
for improved MRI parameters. Such profound structural
improvements to healing tendon in this short term large
animal study lend further support to the notion that
pluripotent stem cells can effect musculoskeletal regen-
eration, rather than repair, even without in vitro lineage
specific differentiation. Further investigation into the
safety of pluripotent cellular therapy as it relates to kar-
yotypic stability, maintained cellular localization and
avoidance of uncontrolled differentiation, as well as the
mechanisms by which repair was improved, need to be
determined.
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Additional File 1: rt-PCR primer and probe sequences. Sequences (5’
to 3’) for forward and reverse primers and probes used in quantitative
PCR. Sequences were selected from equine specific sequences published
in GenBank.
Additional File 2: Gross morphology. Photographs of the superficial
digital flexor tendon (SDFT) in cross-section at 17 cm distal to the
accessory carpal bone (lateral is to the right) and of the palmar surface
of the mid-metacarpal SDFT. A) fetal-derived Embryonic-like stem cell
treated tendons and B) placebo control treated tendons. Asterisks mark
proximolateral in images of the palmar surface.
Additional File 3: Gene expression and biochemical data. Selected
gene expression and total collagen, proteoglycan and DNA content of
fetal-derived embryonic-like stem cell versus placebo control treated
tendon following collagenase induction of injury. There were no
significant differences between either group for any parameter.
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